LeMaitre Vascular, Inc. (NASDAQ:LMAT) Holdings Boosted by Fmr LLC

FMR LLC increased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 330.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,568 shares of the medical instruments supplier's stock after acquiring an additional 8,114 shares during the quarter. FMR LLC's holdings in LeMaitre Vascular were worth $982,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in LMAT. NBC Securities Inc. raised its position in LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 183 shares during the last quarter. West Oak Capital LLC purchased a new stake in LeMaitre Vascular in the 2nd quarter worth $58,000. USA Financial Formulas bought a new stake in LeMaitre Vascular during the 3rd quarter valued at approximately $60,000. nVerses Capital LLC raised its position in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock valued at $66,000 after buying an additional 200 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock worth $68,000 after buying an additional 188 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded down $1.17 on Tuesday, hitting $90.93. The stock had a trading volume of 591,412 shares, compared to its average volume of 129,371. The company's 50 day moving average price is $97.70 and its 200-day moving average price is $89.71. LeMaitre Vascular, Inc. has a 1 year low of $52.88 and a 1 year high of $109.58. The firm has a market capitalization of $2.04 billion, a P/E ratio of 49.86, a P/E/G ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period last year, the business earned $0.33 EPS. The company's revenue was up 15.6% on a year-over-year basis. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.70%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 34.97%.

Analyst Ratings Changes

A number of research firms recently weighed in on LMAT. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday. Barrington Research boosted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. Oppenheimer reiterated an "outperform" rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target on the stock. Finally, JMP Securities raised their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of "Moderate Buy" and an average target price of $94.57.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares of the company's stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.79% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.